Functional assessment of mouse complement pathway activities and quantification of C3b/C3c/iC3b in an experimental model of mouse renal ischaemia/reperfusion injury

Journal of Immunological Methods

Volumn 419, Issue 1, 2015, Pages 25-34

  Kotimaa, Juha P ^a   van Werkhoven, Maaike B ^b   O'Flynn, Joseph ^a   Klar Mohamad, Ngaisah ^a   van Groningen, Jan ^c,d   Schilders, Geurt ^c   Rutjes, Helma ^c,d   Daha, Mohamed R ^a,b   Seelen, Marc A ^b   van Kooten, Cees ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Hycult Biotech   (Netherlands)

^d Pivot Park Screening Centre   (Netherlands)

Author keywords

Alternative pathway; Classical pathway; Lectin pathway; Mouse; Renal ischaemia reperfusion injury; The complement system

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR I; CREATININE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2 11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; KIDNEY ISCHEMIA; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PROCEDURES; REPRODUCIBILITY; TIME; VASCULARIZATION;

MURINAE;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT C3C; COMPLEMENT C9; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; KIDNEY; MICE, INBRED C57BL; MICE, KNOCKOUT; REPERFUSION INJURY; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 84933049065     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.02.010     Document Type: Article

References (39)

1. Amara U., Rittirsch D., Flierl M., Bruckner U., Klos A., Gebhard F., Lambris J.D., Huber-Lang M. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 2008, 632:71. 10.1007/978-0-387-78952-1_6.
2. Arumugam T.V., Shiels I.A., Woodruff T.M., Granger D.N., Taylor S.M. Ischemia-reperfusion injury. Shock 2004, 21:401. 10.1097/01.shk.0000121227.73012.86.
3. Collard C.D., Vakeva A., Morrissey M.A., Agah A., Rollins S.A., Reenstra W.R., Buras J.A., Meri S., Stahl G.L. Complement activation after oxidative stress: role of the lectin complement pathway. Am. J. Pathol. 2000, 156:1549. 10.1016/S0002-9440(10)65026-2.
4. Danobeitia J.S., Djamali A., Fernandez L.A. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair 2014, 7:16. 10.1186/1755-1536-7-16.
5. De Vries B., Kohl J., Leclercq W.K.G., Wolfs T.G.A.M., van Bijnen A.A.J.H.M., Heeringa P., Buurman W.A. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J. Immunol. 2003, 170:3883. 10.4049/jimmunol.170.7.3883.
6. De Vries B., Matthijsen R.A., Wolfs T.G.A.M., Van Bijnen A.A.J.H.M., Heeringa P., Buurman W.A. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003, 75:375. 10.1097/01.TP.0000044455.05584.2A.
7. De Vries D.K., Lindeman J.H.N., Tsikas D., De Heer E., Roos A., De Fijter J.W., Baranski A.G., Van Pelt J., Schaapherder A.F.M. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2009, 9:1574. 10.1111/j.1600-6143.2009.02675.x.
8. Hong K., Kinoshita T., Kitajima H., Inoue K. Inhibitory effect of K-76 monocarboxylic acid, an anticomplementary agent, on the C3b inactivator system. J. Immunol. 1981, 127:104.
9. Kirschfink M., Mollnes T.E. Modern complement analysis. Clin. Diagn. Lab. Immunol. 2003, 10:982. 10.1128/CDLI. 10.6.982-989.2003.
10. Kishore U., Reid K.B. C1q: structure, function, and receptors. Immunopharmacology 2000, 49:159. 10.1016/S0162-3109(00)80301-X.
11. Klerx J.P., Beukelman C.J., Van Dijk H., Willers J.M. Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J. Immunol. Methods 1983, 63:215.
12. Kotimaa J., van der Pol P., Leijtens S., Klar-Mohammad N., Schilders G., Daha M.R., Rutjes H., van Kooten C. Functional assessment of rat complement pathway activities and quantification of soluble C5b-9 in an experimental model of renal ischemia/reperfusion injury. J. Immunol. Methods 2014, 412:14. 10.1016/j.jim.2014.06.011.
13. Lesher A.M., Song W.-C. Review: complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010, 15:663. 10.1111/j.1440-1797.2010.01373.x.
14. Lesher A.M., Zhou L., Kimura Y., Sato S., Gullipalli D., Herbert A.P., Barlow P.N., Eberhardt H.U., Skerka C., Zipfel P.F., Hamano T., Miwa T., Tung K.S., Song W.-C. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis. J. Am. Soc. Nephrol. 2013, 24:53. 10.1681/ASN.2012060570.
15. Mastellos D., Prechl J., László G., Papp K., Oláh E., Argyropoulos E., Franchini S., Tudoran R., Markiewski M., Lambris J.D., Erdei A. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol. Immunol. 2004, 40:1213. 10.1016/j.molimm.2003.10.019.
16. May J.E., Frank M.M. A new complement-mediated cytolytic mechanism-the C1-bypass activation pathway. Proc. Natl. Acad. Sci. U. S. A. 1973, 70:649. 10.1073/pnas.70.3.649.
17. McCullough J.W., Renner B., Thurman J.M. The role of the complement system in acute kidney injury. Semin. Nephrol. 2013, 33:543. 10.1016/j.semnephrol.2013.08.005.
18. Miwa T., Sato S., Gullipalli D., Nangaku M., Song W.-C. Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice. J. Immunol. 2013, 190:3552. 10.4049/jimmunol.1202275.
19. Møller-Kristensen M., Wang W., Ruseva M., Thiel S., Nielsen S., Takahashi K., Shi L., Ezekowitz A., Jensenius J.C., Gadjeva M. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand. J. Immunol. 2005, 61:426. 10.1111/j.1365-3083.2005.01591.x.
20. Nauta A.J., Daha M.R., Tijsma O., Van De Water B., Tedesco F., Roos A. The membrane attack complex of complement induces caspase activation and apoptosis. Eur. J. Immunol. 2002, 32:783. 10.1002/1521-4141(200203)32:3<783::AID-IMMU783>3.0.CO;2-Q.
21. Ong G.L., Mattes M.J. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Methods 1989, 125:147. 10.1016/0022-1759(89)90088-4.
22. Oppermann M., Götze O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 1994, 82:516.
23. Otten M.A., Groeneveld T.W.L., Flierman R., Rastaldi M.P., Trouw L.A., Faber-Krol M.C., Visser A., Essers M.C., Claassens J., Verbeek J.S., van Kooten C., Roos A., Daha M.R. Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J. Immunol. 2009, 183:3980. 10.4049/jimmunol.0901301.
24. Palarasah Y., Skjoedt M.-O., Vitved L., Andersen T.E., Skjoedt K., Koch C. Sodium polyanethole sulfonate as an inhibitor of activation of complement function in blood culture systems. J. Clin. Microbiol. 2010, 48:908. 10.1128/JCM. 01985-09.
25. Petersen S.V., Thiel S., Jensenius J.C. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol. Immunol. 2001, 38:133. 10.1016/S0161-5890(01)00038-4.
26. Pfeifer P.H., Kawahara M.S., Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin. Chem. 1999, 45:1190.
27. Roos A., Bouwman L.H., Munoz J., Zuiverloon T., Faber-Krol M.C., Fallaux-van den Houten F.C., Klar-Mohamad N., Hack C.E., Tilanus M.G., Daha M.R. Functional characterization of the lectin pathway of complement in human serum. Mol. Immunol. 2003, 39:655. 10.1016/S0161-5890(02)00254-7.
28. Schwaeble W.J., Lynch N.J., Clark J.E., Marber M., Samani N.J., Ali Y.M., Dudler T., Parent B., Lhotta K., Wallis R., Farrar C.A., Sacks S., Lee H., Zhang M., Iwaki D., Takahashi M., Fujita T., Tedford C.E., Stover C.M. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7523. 10.1073/pnas.1101748108.
29. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjöholm, a G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., Alexopoulos E., Turner M.W., Daha M.R. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 2005, 296:187. 10.1016/j.jim.2004.11.016.
30. Spitzer D., Mitchell L.M., Atkinson J.P., Hourcade D.E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 2007, 179:2600. 10.4049/jimmunol.179.4.2600.
31. Sutton T.A., Fisher C.J., Molitoris B.A. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002, 62:1539. 10.1046/j.1523-1755.2002.00631.x.
32. Thurman J.M., Royer P.A., Ljubanovic D., Dursun B., Lenderink A.M., Edelstein C.L., Holers V.M. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 2006, 17:707. 10.1681/ASN.2005070698.
33. Thurman J.M., Kulik L., Orth H., Wong M., Renner B., Sargsyan S.A., Mitchell L.M., Hourcade D.E., Hannan J.P., Kovacs J.M., Coughlin B., Woodell A.S., Pickering M.C., Rohrer B., Holers V.M. Detection of complement activation using monoclonal antibodies against C3d. J. Clin. Invest. 2013, 123:2218. 10.1172/JCI65861.
34. Trouw L.A., Groeneveld T.W.L., Seelen M.A., Duijs J.M.G.J., Bajema I.M., Prins F.A., Kishore U., Salant D.J., Verbeek J.S. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes 114 2004, (The). 10.1172/JCI200421075.
35. Trouw L.a., Seelen M.A., Duijs J.M.G.J., Wagner S., Loos M., Bajema I.M., van Kooten C., Roos A., Daha M.R. Activation of the lectin pathway in murine lupus nephritis. Mol. Immunol. 2005, 42:731. 10.1016/j.molimm.2004.09.024.
36. Van der Pol P., Schlagwein N., van Gijlswijk D.J., Berger S.P., Roos a., Bajema I.M., de Boer H.C., de Fijter J.W., Stahl G.L., Daha M.R., van Kooten C. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am. J. Transplant. 2012, 12:877. 10.1111/j.1600-6143.2011.03887.x.
37. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058. 10.1056/NEJM200104053441406.
38. Wetsel R.A., Fleischer D.T., Haviland D.L. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J. Biol. Chem. 1990, 265:2435.
39. Zhou W., Farrar C.a., Abe K., Pratt J.R., Marsh J.E., Wang Y., Stahl G.L., Sacks S.H. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 2000, 105:1363. 10.1172/JCI8621.